Two monoclonal antibodies targeting B cells have been used successfully in refractory SLE: belimumab directed against B-cell activating factor (BAFF) [5] and Rituximab which is a genetically engineered chimeric anti-CD20 monoclonal antibody. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.